Market Insights

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

The KRAS inhibitors market is projected to witness strong expansion, fueled by the growing burden of cancer, wider access to advanced therapies, and a promising pipeline featuring candidates such as Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revolution Medicines), Onvansertib

19 November 2025

Market Insights·Uncategorised

Global Pharmaceutical Contract Manufacturing Market Expected to Exceed USD 360 Billion by 2032 | DelveInsight

The pharmaceutical contract manufacturing market is witnessing robust growth, largely fueled by the increasing prevalence of chronic and infectious diseases. This expansion is further supported by the growing demand for biologics and biopharmaceuticals. Additionally, pharmaceutical and biotechnology companies are actively strengthening their

20 November 2025

Market Insights

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

DelveInsight’s “EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034” report provides an in-depth analysis of the EGFR Inhibitor market, including historical and projected epidemiology trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom,

19 November 2025

Market Insights

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

The introduction of novel therapies, including BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), among others, is poised to reshape the myelofibrosis treatment landscape. DelveInsight’s Myelofibrosis Market Insights report includes

19 November 2025

Market Insights

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

The NPC market remains constrained by the scarcity of approved therapies and a substantial unmet medical need. Nonetheless, upcoming treatments, including Cyclo Therapeutics’ Trappsol Cyclo, Azafaros’ oral small-molecule nizubaglustat (AZ-3102), and the early-stage candidate Adrabetadex (VTS-270), combined with increasing disease awareness, are

19 November 2025

Market Insights

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

The TNBC market is projected to expand, driven by rising disease prevalence, advances in targeted treatment options, and the introduction of new therapies, including DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine

19 November 2025

Market Insights

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

Global Pharmaceutical Contract Manufacturing Market Expected to Exceed USD 360 Billion by 2032 | DelveInsight

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

Recent Posts

Recent Comments

Hi There!

Banner

Latest Interviews

Newsletter

Authors

pharmaglobenews

Rachel Hartley

FDA Approves Amgen’s IMDELLTRA (Tarlatamab-dlle): A Breakthrough in Extensive Stage Small Cell Lung Cancer Treatment

Suggestions

Market Insights

Recent Posts

Recent Comments

Hi There!

Banner

Latest Interviews

Newsletter

Authors